Bharat Biotech's Covaxin shows 77.8% efficacy in phase 3 trial data: Report

Covaxin has shown the efficacy from the trial conducted on 25,800 subjects, according to a news report

Bharat Biotech's Covaxin is said to have shown 77.8 % efficacy in phase 3 trial data in review by Subject Expert Committee under the drug regulator, sources told ANI on Tuesday.

According to the data submitted, Covaxin has shown efficacy of 77.8% from the trial conducted on 25,800 subjects, according to a news report

The meeting took place before Bharat Biotech's 'pre-submission' meeting on Wednesday with the World Health Organization (WHO), for the approval for their Covid vaccine.

The Hyderabad-based Covid vaccine manufacturing company submitted data from the phase 3 clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over